RESEARCH TRIANGLE PARK, N.C. – April 21, 2004 – Quintiles Transnational Corp. today announced the appointment of three of the world's leading cardiac experts to form an advisory panel for Quintiles' Integrated Cardiac Safety Services.
The members of the expert panel are available for consultation with any Quintiles Integrated Cardiac Safety customer, complementing an already high level of expertise in Quintiles' experienced staff of 15 in-house cardiologists.
The three experts are David Benditt, M.D., Professor of Medicine at the University of Minnesota Medical School, USA; Arvinder Kurbaan, M.D., Consultant Cardiologist to St. Bartholomew Hospital, London, England; and Richard Sutton, DScMed, Consultant Cardiologist and Director of Pacing, Royal Brompton & Harefield National Health Service Trust, London, and Consultant Cardiologist to Chelsea & Westminster Hospital, London.
"Cardiac safety data often needs the experienced eye of an expert," said David A. Dworaczyk, Ph.D., Sr. Vice President, Integrated Technologies. "Drs. Benditt, Kurbaan and Sutton are world leaders in cardiology. They will be available to provide expert guidance to our customers, helping to identify and understand cardiac safety issues as they arise in the drug development process."
Benditt has done extensive research on coronary sinus catheters, resulting in seven patents. He has held numerous positions including the presidency of both the North American Society for Pacing and Electrophysiology and the Minnesota affiliate of the American Heart Association.
Sutton, who holds six patents on cardiac devices, helped develop the cardiology practice at Westminster Hospital in London, which became one of the major implantation centers in the U.K.
Kurbaan has been involved in numerous research projects, including a registry analysis of coronary stents, development of a database on management of syncope – the partial or complete loss of consciousness due to a temporary reduction of blood flow – and a comparison of angioplasty with bypass surgery.
"Going forward, medicines in development must meet evolving cardiac safety standards," Dworaczyk said. "Through their research, the members of our panel have contributed significantly to the medical community's understanding of the human heart and how it functions. I believe their guidance will be invaluable for pharmaceutical and biotechnology companies developing new therapies for cardiac care."
About Quintiles' Integrated Cardiac Safety Services
Integrated Cardiac Safety offers an integrated approach to cardiac safety, spanning preclinical development through post-marketing surveillance. With resources positioned globally, Cardiac Safety has trained and experienced cardiologists available 24 hours a day, seven days a week for real-time and retrospective ECG review and signoff. Cardiac Safety also offers a 24-hour Help Desk as well as a multi-lingual call center to support clinical trials around the world.
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at www.quintiles.com.